DirectConnect Inside Yale Cancer Center

September 5, 2014

Announcements

Closer to Free Ride Tomorrow!

I'm looking forward to seeing you all at our 4th annual Closer to Free Ride tomorrow at the Yale Bowl. If you are not already participating, please consider stopping by one of the many cheer stations to cheer on our patients and your friends and colleagues.

View a list of Cheer Stations here.

Following the ride, all employees are invited to the Yale Bowl for the day-long celebration with live music, BBQ, and plenty of family and kids' activities.

Ashita Talsania, MD Joins Torrington Care Center

I am pleased to welcome Dr. Ashita Talsania, Assistant Professor of Medical Oncology, to the Smilow Cancer Care Center in Torrington. Dr. Talsania will care for patients four days a week in Torrington and will be in New Haven one day a week to participate in activities with the Hematology and Thoracic Oncology Programs, including their Tumor Boards and Clinical Trial planning meetings.

Dr. Talsania joins Yale Cancer Center from Baystate Medical Center in Springfield, MA where she recently completed her fellowship in hematology/oncology and a residency in internal medicine. She received her medical degree from D.Y.Patil Medical School at Mumbai University in India.

SU2C on Air Tonight

The annual live broadcast of Stand Up To Cancer's program and fundraising event will air tonight on all four major television networks at 8 PM. Yale Cancer Center's Dr. Patricia LoRusso is co-leader of the

from the desk of Thomas J. Lynch, Jr., MD Director, Yale Cancer Center Physician-in-Chief Smilow Cancer Hospital at Yale-New Haven



A Comprehensive Concer Center Designated to the National Cancer Institute


Recent News

Read recent articles featuring experts from Yale Cancer Center News Center>>

LATEST ARTICLES:



Commentary: It's Time to Repackage the Fight Against Cigarettes Read More >>



The front line in battle against cancer Read More >>

SU2C Melanoma-MRA Dream Team and will be in attendance at tonight's live broadcast. The goal of her research team's efforts is to sequence melanoma tumors and create a "personalized medicine" approach to lead to more effective and lasting treatments for patients with advanced and metastatic melanoma. The television program is SU2C's flagship fundraising and awareness event each year.

CME Programs in September

Please join us for two continuing education programs at Smilow Cancer Hospital in September. On Tuesday, September 9at 5 PM we will host a CME Dinner Symposium highlighting treatment and research advances in Melanoma and Renal Cell Carcinoma and on Friday, September 12 at 8 AM we will host a Symposium at 55 Park Street on Gastrointestinal Cancers. Please register to join us for these two important programs. Learn More >>

Publicity for your Research

If you would like your research to be considered for publicity, please let <u>Vicky Agnew</u> and <u>Renee</u> <u>Gaudette</u> know as soon as you receive word of acceptance for publication or presentation at a conference. Early notice will give them a chance to shape and position the findings for stories in the news media and various Yale news outlets. All journal guidelines regarding announcements and embargoes will be followed.

Yale Presents at ASTRO

Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven will once again be well represented at the annual American Society for Radiation Oncology (ASTRO) beginning on September 14 in San Francisco. Congratulations to the following faculty members on their participation:

Lynn Wilson served as Chairman of the ASTRO Annual Meeting Scientific Committee for the third year of his three-year term and as Chairman of the Annual Meeting Steering Committee.

Sara Rockwell and **Lynn Wilson** are ASTRO Fellows.

Ranjit Bindra will be honored at the meeting with an Educator of the Year Award recognizing his outstanding contribution to the education and



What is cancer immunotherapy? Read More >>

Follow Yale Cancer Center on Twitter

Follow us on twitter

LATEST TWEETS:

✓ It is a big weekend for those who care about cancer research & treatment. Friday brings us @SU2C on TV. Saturday is @YNHH @ridecloser2free

Dr. Mario Sznol joins roundtable on immune therapy in Life Science Magazine Combination Cancer Immunotherapy http://shar.es/11CZu2

Lupus antibodies sabotage cancer cells with deficient dna repair. Another way to attack #cancer

✓ Two things to do over the long weekend: Register for the @ridecloser2free ride; and see us ... @YNHH

There's still time to register for @ridecloser2free but don't delay. Tick tock! http://www.rideclosertofree.org/

✓ It's time to repackage the fight against cigarettes http://bit.ly/1qh0xKQ @bentollyale @yale @OncLive

Join Yale Cancer Center on Facebook

mentoring of radiation oncology residents.

Moderating Roles:

Plenary Session and Clinical Trials Session Lynn Wilson

Breast - Biology/Nodal Management Meena Moran

Biology - Molecular Biology of Lung Cancer Ranjit Bindra

Head and Neck - Biology and New Technology Zain Husain

Radiobiology of High-Dose Stereotactic Radiotherapy and Physics 4 David Carlson

Educational Symposiums and Scientific Sessions:

To Treat or Not to Treat: Decision Making and Treatment Options in Low-risk Prostate Cancer: Risk versus Benefit Vanna Dest, MSN, APRN, AOCN Pamela Devine, MSN, RN

Challenging Cases in CNS Cancer Joachim Baehring, MD, DSc James Yu, MD

Pediatric Brain Tumors Ranjit Bindra, MD, PhD

Extranodal Non Hodgkin's Lymphoma: Recent Advances in the Management of CNS, Orbital and Cutaneous Lymphomas Lynn Wilson, MD, MPH, FASTRO

Improving Patient Safety and Quality of Care with the Radiation Oncology Incident Learning System (RO ILS) Suzanne Evans, MD

ASTRO Guidelines Highlight Breast Margins Meena S. Moran, MD

Understanding the New Evidence: A Comparative Effectiveness Research Primer for the Radiation Oncologist Cary Gross, MD Like us on Facebook f

LATEST POSTS:

The 4th Annual Ride Closer to Free is only 2 days away! We are looking forward to welcoming over 1,000 riders on Saturday to our biggest event yet. 100% of funds raised by participants and volunteers benefit patient programs at Smilow Cancer Hospital at Yale-New Haven and cancer research at Yale Cancer Center.

With the opening ceremony at 6:45am, the ride beginning at 7:00am, and fun & festivities until 5:00pm, this Saturday is sure to be an amazing day to celebrate life and fight back against cancer.



More >>

Tune in to Yale Cancer Center Answers at 6 PM this evening on WNPR or <u>www.wnpr.org</u> to listen to an interview with Dr. Xavier Llor, Medical Director of the Colorectal Cancer Prevention Program and Co-Director of the Smilow Cancer Genetics and Prevention Program.

In addition to regularly caring for patients, Dr. Llor has a very active basic and translational research program mainly focusing on two different aspects of colorectal cancer: hereditary and familial forms, and disparities in colorectal cancer.



Read More>>

Our immune systems are amazing; they work to make sure infections do not repeatedly harm a person, a condition known as a superinfection. Despite its

James Yu, MD

Presentations:

Elderly Patients Undergoing SBRT for Inoperable Early Stage NSCLC Achieve Similar Outcomes to Younger Patients Brandon Mancini

High-Throughput RNAi Screening Platform Identifies Novel Regulators of DNA Double-Strand Break Repair Pathways Ahmed Salem

Evaluating National Practice in Breast Cancer Radiotherapy for Elderly Women: Response to a Randomized Trial and Cost Effectiveness on a National Scale Charles Rutter

Predictors of Vaginal Stenosis Following Intravaginal High-Dose-Rate Brachytherapy for Endometrial Carcinoma Shari Damast

Dose-Volume Parameters for the Esophagus in Pulmonary SBRT Eileen Harder

Does Central vs. Peripheral Tumor Location Impact Outcomes Following Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer? Henry Park

Trends in Stage I Lung SBRT Clinical Practice Patterns Christopher Corso

Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Roy Decker


Cost Effectiveness of Biopsy Prior to Stereotactic Body Radiotherapy (SBRT) For Screening-Detected FDG-Avid Lung Nodules Nataniel Lester-Coll

Comparative Effectiveness of Stereotactic Body Radiotherapy Vs. Surgery for Stage I Non-Small Cell Lung Cancer James Yu

Serial Imaging of Tumor Hypoxia in Early Stage Non-

effectiveness, we still know little about how the immune system works.

In an article published this week, Dr. Akiko Iwasaki, Professor of Immunobiology and researcher for Yale Cancer Center and Howard Hughes Medical Institute, and Dr. Norifumi Iijima, help to explain this mystery. Their findings suggest a biological basis for new vaccines against sexually transmitted diseases, and possibly HIV, say the researchers, who note a similar approach might be applied to cancer vaccines as well.



More>>

Although friends and family provide love, care, and comfort, many cancer patients find that few truly understand the tumultuous times of cancer treatment. That is why Smilow Cancer Hospital at Yale-New Haven offers patients and family members 18 different support groups to help cope with the psychological challenges of cancer.

Recently, the Young Adult Cancer Support Group gave <u>WTNH News 8</u>'s Jocelyn Maminta a glimpse of what they call a "lifeline for survival." Jocelyn talks with four cancer patients, Nicole, Jaime, Jennifer, and Todd, about the support they receive from the group.



More>>

<u>Read</u>

Closer to Free



Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy David Carlson

Poster Sessions:

Historical Trends of Radiotherapy Use in Prevalent Malignancies Debra Yeboa

Impact Of Three Decades Of Screening On Racial Disparities In Cervical Cancer Incidence Daniel Yang

Optimized Prostate Intrafraction Motion Management IGRT Strategy for 3mm Margin Wu Liu

Metallothioneins in Fibrosis: Implications for Radiation-induced Fibrosis Adriana Blakaj

The Impact of New EMR Adoption on the Number of Radiology Exams Ordered in a Busy Radiation Oncology Clinic Sean Maroongroge

ACE Inhibitors Decrease the Risk of Radiation Pneumonitis Following SBRT Eileen Harder

Systemic Treatment And Radiation Necrosis Following Gamma Knife Radiosurgery In The Treatment Of Brain Metastases Rovel Colaco

Change in Radiotherapy Treatment Volumes with Initial Alkylating Chemotherapy in WHO Grade III Gliomas Vikram Jairam

Robotic Stereotactic Body Radiotherapy for Prostate Adenocarcinoma Shane Lloyd

Demographic Disparities in SBRT Utilization for Stage I NSCLC Christopher Corso

Effect Of Primary Treatment Modality On The Association Between Statins And Prostate Cancer Recurrence: An Updated Meta-Analysis Henry Park

Events

September 6; 6:00 AM

Yale Cancer Center/Smilow Cancer Hospital Closer to Free Bike Ride Yale Bowl Read More >>

September 7; 6:00 PM Yale Cancer Center Answers WNPR Melanoma Awareness and Treatment Dale Han, MD and Amanda Ralabate, RN Read More >>

September 9; 12:00 PM Yale Cancer Center Grand Rounds Park Street Auditorium Breaking the Barrier of Acquired Resistance Thomas Lynch, Jr., MD Strategies to Overcome and Prevent Resistance to EGFR-directed Therapies in Lung Cancer Katerina Politi, MD Read More >>

September 9; 4:30 PM Yale Cancer Center Oncology Series NP 4-101 A & B Melanoma and Renal Cell Carcinoma Thomas Lynch, Jr., MD Read More >>

September 10; 1:00 PM YCC Cancer Metabolism Interest Group (CMIG)

Giarman Room-SHM B-201 A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia Min-Dian Li Read More >> (PDF)

September 11; 5:00 PM YCC/SCH/AIM at Melanoma Event Park Street Auditorium

2014 Melanoma Symposium Read More >> (PDF)

September 12; 7:00 AM Yale CME Event The Effect of Diabetes and Antidiabetic Drugs on Outcomes after Pulmonary SBRT Eileen Harder

Dose Selection Algorithm For Gamma Knife Treatment Of Cerebral Metastases - Preliminary Results Rovel Colaco

Radiation Oncologists' Opinions about Palliative Radiation Therapy for Patients on Hospice Care Shane Lloyd

Predicting the Relative Biological Effectiveness of Carbon Ion Radiotherapy Beams using the Mechanistic Repair-Misrepair-Fixation (RMF) Model and Nuclear Fragment Spectra David Carlson

Notables

Don Nguyen, PhD, a member of the Yale Cancer Center Signal Transduction Program, was awarded a 2-year R21 grant from the NCI, entitled: "Epigenetic modulation of lung cancer metastasis by a novel long intergenic RNA." The project will be done in collaboration with Dr. David Rimm.

Melinda Irwin, PhD, Co-director of the Cancer Prevention and Control Program, has received a grant from the CT Breast Health Initiative to support dissemination of Lifestyle, Exercise, and Nutrition (LEAN) Study intervention by testing her team's LEAN book as an intervention without the addition of counseling.

Tessa Steffen joined the Yale Cancer Center Director's Office as a Senior Administrative Assistant supporting Kevin Vest and Vicky Agnew. Tessa most recently worked as a Junior Nuclear Weapons Program Analyst for the Department of Energy/National Nuclear Security Administration. Tessa can be reached at (203) 785-4095.

YCC Member Survey

As many of you are aware, Yale Cancer Center has

Park Street Auditorium Update In Gastrointestinal Cancer Harry Aslanian, MD Read More >> (PDF)

September 12; 1:00 PM YCC Molecular Virology Research Program SHM I-304 New Inhibitors of Epstein-Barr Virus Reactivation Kelly Gorres, PhD Read More >> (PDF)

September 14; 6:00 PM Yale Cancer Center Answers WNPR *Clinical Trials for Smoking Cessation* Steven Bernstein, MD <u>Read More >></u>

September 16; 12:00 PM

Yale Cancer Center Grand Rounds Park Street Auditorium Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNF in glioblastoma Sourav Ghosh, PhD TBD Kerin Adelson, MD Read More >>

September 18; 5:00 PM

Free Prostate Cancer Screening McGivney Cancer Center/St. Raphael's Campus Read More >> (PDF)

September 18; 5:00 PM Yale Stem Cell Center Seventh Annual Retreat Yale's West Campus Breast Tumor Evolution Kornelia Polyak, MD, PhD Read More >> (PDF)

September 19; 5:15 PM Yale Stem Cell Center Seventh Annual Retreat Yale's West Campus Neuronal Plasticity and Genomic Diversity Fred H. Gage, PhD Read More >> (PDF) recently embarked on an effort to develop a new strategic plan. We are eager to incorporate the input from our members into the planning process, and to that end, request that you complete a brief, web-based survey. All responses will be kept completely confidential by the consulting firm engaged to facilitate the strategic planning process. The survey will remain open through September 15. Thank you in advance for your contributions.

Complete Survey >>

Research in the News

Researchers try to make sure herpes does not find a home

The immune system is great at making sure infections such as the herpes virus do not repeatedly infect a person, a condition known as a superinfection. Yet how the immune system combats superinfection is not well understood.

Yale Cancer Center researchers found that a lymphocyte network helps retain a specific type of T cell in the tissue of the vaginas of mice that have previously encountered herpes infection; this, in turn, prevents infection by the herpes simplex virus. The findings suggest a biological basis for new vaccines against sexually transmitted diseases, and possibly HIV, say the researchers, who note a similar approach might be applied to cancer vaccines as well.

Read More >>

Sabotage as therapy: aiming lupus antibodies at vulnerable cancer cells

Yale Cancer Center researchers may have discovered a new way of harnessing lupus antibodies to sabotage cancer cells made vulnerable by deficient DNA repair.

The findings were published recently in Nature's journal Scientific Reports.

The study, led by James E. Hansen, M.D., assistant professor of therapeutic radiology at Yale School of Medicine, found that cancer cells with deficient DNA repair mechanisms (or the inability to repair their own genetic damage) were significantly more vulnerable to attack by lupus antibodies.

Employment Opportunities

Success in any clinical research endeavor, but especially in cancer research, requires the most qualified, dedicated staff, committed to excellence and the mission of Yale Cancer Center. The combination of education, oncology research experience, and exceptional nursing skills is enormously difficult to find. Your participation, as knowledgeable colleagues, is invaluable at this time.

Should you know individuals with outstanding clinical research nursing experience, and who are ready to join our team, please direct resumes to <u>Sandra</u> <u>Greer</u>, Sr. Staffing and Career Development Representative or call (203) 432-5822. All referrals will be held in strictest confidence.

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Marketing renee.gaudette@yale.edu

Experience Forward to a Friend

Read More >>

Employee Profile: Theresa Petrone

The Employee Profile recognizes the diverse contributions made by Yale Cancer Center and Smilow Cancer Hospital staff to meet our patient care, research, education, and outreach goals. The staff profiled are examples of the great work being done here, and the dedication and values we possess.

To suggest someone to be profiled, please contact *Emily Fenton*.

Theresa Petrone, RN,

started as an RN volunteer at Smilow and within five months she became a full-time Oncology Nurse on Smilow 14-NP. During her nearly four years on the floor, she has achieved a great deal in her quest to provide the best patient care possible. She



earned her OCN Oncology certification, she was awarded the Daisy Award for Extraordinary Nurses, and for the last year she has volunteered to be a Quality and Safety intern for the new Quality internship program. In addition, she also sits on the hospital-wide Council for Quality and Safety.

The Daisy Award is a national award to honor nurses in memory of J. Patrick Barnes. The award was created to let nurses know how deserving they are of society's profound respect for the education, training, brainpower, and skill they put into their work. Theresa commented, "Taking care of my patients is the best part of my job, and I love doing it. My goal is to provide these women with the best care and experience possible. Some patients are receiving chemotherapy while others are recovering from major surgeries. I also want to be sure they have access to all the wonderful support services Smilow has to offer, such as Reiki, yoga, social workers, translators, and specialized nutritionists." Theresa wanted to be a Quality and Safety Intern to further extend her ability to impact patient care and advocate for patients by helping to build good practices into the system. "Improving the systems under which we provide care is the best way to positively impact the most patients," said Theresa. In this role she tries to expand nurses' knowledge about the safety of patients and providing quality, attentive care. The Council for Quality and Safety is a multidisciplinary, hospital-wide group that meets with a focus on quality indicators and how they can be improved. The Council identifies issues and discusses solutions to resolve them. Their current focus is on patient identification and pain and improving pain scores.

Supporting families is another important part of what Theresa does. An all-women's floor can be intimidating to male family members who feel out of place while they also deal with the deep emotional burden of facing a loved-one's illness. Theresa makes sure to make family members feel supported so that they can be positive influences while the patient heals. Tracy Carafeno, RN, MS, Patient Service Manager for Women's Services and Surgical Oncology, commented, "Theresa comes to work every day with a smile and a positive attitude. She is dedicated, compassionate and always puts her patients and families first. She has made a difference in the lives of so many women. NP 14 is very proud and honored to have Theresa as a team member."

Funding and Award Opportunities

Alliance for Cancer Gene Therapy Young Investigator Award

Alliance for Cancer Gene Therapy, Inc. (ACGT) funds research aimed at furthering the development of cell and gene therapy approaches to the treatment of cancer. To this end, ACGT offers its Young Investigator Award to qualified scientists at the Tenure Track Assistant Professor level. The overall objectives of this grant are to advance cell and gene therapy into the causes, treatment and prevention of all types of cancer by promoting development of novel and innovative studies by young investigators. The emphasis of this initiative is to promote basic and pre-clinical research approaches utilizing cells and genes as medicine. ACGT will direct its grants into areas of cell and gene therapy research that have demonstrated great promise. **Application Deadline:** September 16, 2014 Learn More >> (PDF)

Prostate Cancer Foundation 2014 PCF Global Treatment Sciences Challenge Awards

Grants of up to \$1 million over 2-3 years will be awarded for research projects related to lethal prostate cancer. (PCF expects to fund 5-10 of these awards.) Priority will be given to high risk, first-infield, and currently unfunded projects. Funding will support the correlative research around either clinical trials of novel agents or strategies of standard of care. The foundation's emphasis is on developing or validating biomarkers that guide therapy in patients or further understanding of the mechanism by which therapies work. While the focus is on research in humans, the actual trials or treatments themselves will not be supported. Human samples are highly preferred, although at times model systems might be required to complement the understanding of an important mechanism.

Application Deadline: September 22, 2014 Learn More >> (PDF)

Center for Cancer Research Clinical Investigator Development Program

The Center for Cancer Research (CCR), a Division of the National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), is pleased to announce its annual call for applications for Clinical Investigator Development Program (CIDP). This is an exciting training opportunity intended for physicians interested in dedicating their careers to clinical research. Candidates may be U.S. citizens, permanent residents or possess (or be eligible for) the appropriate work visa and must have successfully completed subspecialty training at a U.S.-accredited institution in appropriate fields.

Application Deadline: October 30, 2014 Learn More >>_

Conquer Cancer Foundation - Career Development Award

The Career Development Award (CDA) is a research grant that provides funding to clinical investigators who have received their initial faculty appointment to establish an independent clinical cancer research program. The cancer research must have a patientoriented focus, including a clinical research study and/or translational research involving human subjects.

Application Deadline: September 25, 2014 Learn More >>

Connecticut DPH Biomedical Research Request for Proposals

The Connecticut Department of Public Health is seeking proposals for biomedical research projects in the fields of heart disease, cancer and other tobaccorelated diseases, Alzheimer's disease, stroke and diabetes.

Application Deadline: September 30, 2014 Learn More >>

SPIRIT Pilot Grants

The SPIRIT Group, a collaboration among 6 CTSA programs (Yale, Penn, Pitt, U Chicago, Wash U, and Johns Hopkins), has developed a pilot grant program to promote cross-institution research. Proposed projects should focus on a rare disease, and must involve a collaboration among scientists at each of the 6 institutions. A total of \$300,000 will be awarded.

Letter of Intent Deadline: September 15, 2014 Learn More >>

Free to Breathe Issues Request for Proposals for Lung Cancer Research

Free to Breathe, a partnership of lung cancer survivors, advocates, researchers, healthcare professionals, and industry leaders united in the belief that every person with lung cancer deserves a cure, has issued a Request for Proposals for research projects focused on preventing or stopping lung cancer metastasis.

Grants of up to \$600,000 over three years will be awarded in support of innovative, high-impact lung cancer research that leads to clinical translation (e.g. clinical trial) by the end of the award period. The partnership is particularly interested in proposals that include interdisciplinary teams and two or more principal investigators; collaborations with industry partners (PIs must be employed at a nonprofit entity such as an academic or research institution); access to existing patient samples or data, especially tissue from metastatic sites; studies that include mechanistic investigations into the underlying causes of metastasis; studies that are distinct research components of new or existing clinical trials; and/or novel approaches for preventing brain metastasis. **Application Deadline:** November 7, 2014 Learn More >> (PDF)

Recent Publications

BRAF-inhibition alleviates immune suppression in murine autochthonous melanoma.

Steinberg SM, Zhang P, Malik B, Boni A, Shabaneh T, Byrne K, Mullins DW, Brinckerhoff CE, Ernstoff M, Bosenberg MW, Turk MJ. Cancer Immunol Res. 2014 Sep 2. Read More >>

A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy. Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW,

Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S. Clin Cancer Res. 2014 Sep 1;20(17):4499-510.

Read More >>

New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.

Jürgensmeier JM, Eder JP, Herbst RS. Clin Cancer Res. 2014 Sep 1;20(17):4425-35 <u>Read More >></u>

Polymorphisms in DNA repair genes, hair dye use, and the risk of non-Hodgkin lymphoma.

Guo H, Bassig BA, Lan Q, Zhu Y, Zhang Y, Holford TR, Leaderer B, Boyle P, Qin Q, Zhu C, Li N, Rothman N, Zheng T. Cancer Causes Control. 2014 Sep 2.

Read More >>

Family life events in the first year of acute lymphoblastic leukemia therapy: A children's oncology group report.

Lau S, Lu X, Balsamo L, Devidas M, Winick N, Hunger SP, Carroll W, Stork L, Maloney K, Kadan-Lottick N. Pediatr Blood Cancer. 2014 Aug 30.

Read More >>

A combinatorial microRNA therapeutics approach to suppressing non-small cell

lung cancer.

Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG, Slack FJ. Oncogene. 2014 Sep 1. Read More >>

An analysis of FDA-approved drugs for oncology. Kinch MS. Drug Discov Today, 2014 Aug 27

Drug Discov Today. 2014 Aug 27. Read More >>